Ascendis Pharma A/S (ASND) shares rallied 8.7% in the last trading session to close at $139.66. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.3% loss over the past four weeks.Earlier this week, the FDA approved the company’s hormone replacement therapy, Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of adults with hypoparathyroidism. This might have driven the share price ral ...